8 news items
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR
29 May 24
Disease and Ophthalmology and was accountable for late-stage clinical development of many products including strategy, clinical trials and budget. He
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
therapies or strategies
Date: Wednesday, June 5
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir's strategy
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
registration strategy to bring the best regimens to HBV patients
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
VIR
7 May 24
ratio of 0.08, Vir Biotechnology adopts a prudent financial strategy, indicating a balanced approach to debt management
hqkxqfjm2gmo1iqd00ro48k
ANTX
VBIV
VIR
22 Mar 24
-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy
4vd0eggrqdnvgzbq9ua5qr87zmrf2i5tiohew ls1yxgezi8lrlsvt
VIR
15 Mar 24
of 0.08, Vir Biotechnology adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst
1raxenk4j6 mbyz77
VIR
5 Mar 24
regarding Vir's strategy and plans; the potential benefits, safety and efficacy of tobevibart and elebsiran for the treatment of chronic hepatitis delta
- Prev
- 1
- Next